Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20


Autophagy in 3D In Vitro and Ex Vivo Cancer Models.

Follo C, Barbone D, Richards WG, Bueno R, Courtney Broaddus V.

Methods Mol Biol. 2019;1880:491-510. doi: 10.1007/978-1-4939-8873-0_31.


Autophagy initiation correlates with the autophagic flux in 3D models of mesothelioma and with patient outcome.

Follo C, Barbone D, Richards WG, Bueno R, Broaddus VC.

Autophagy. 2016 Jul 2;12(7):1180-94. doi: 10.1080/15548627.2016.1173799. Epub 2016 Apr 20.


Analysis of Gene Expression in 3D Spheroids Highlights a Survival Role for ASS1 in Mesothelioma.

Barbone D, Van Dam L, Follo C, Jithesh PV, Zhang SD, Richards WG, Bueno R, Fennell DA, Broaddus VC.

PLoS One. 2016 Mar 16;11(3):e0150044. doi: 10.1371/journal.pone.0150044. eCollection 2016.


Autophagy Correlates with the Therapeutic Responsiveness of Malignant Pleural Mesothelioma in 3D Models.

Barbone D, Follo C, Echeverry N, Gerbaudo VH, Klabatsa A, Bueno R, Felley-Bosco E, Broaddus VC.

PLoS One. 2015 Aug 18;10(8):e0134825. doi: 10.1371/journal.pone.0134825. eCollection 2015.


Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors.

Echeverry N, Ziltener G, Barbone D, Weder W, Stahel RA, Broaddus VC, Felley-Bosco E.

Cell Death Dis. 2015 May 7;6:e1757. doi: 10.1038/cddis.2015.124.


BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma.

Busacca S, Chacko AD, Klabatsa A, Arthur K, Sheaff M, Barbone D, Mutti L, Gunasekharan VK, Gorski JJ, El-Tanani M, Broaddus VC, Gaudino G, Fennell DA.

PLoS One. 2013 Jun 7;8(6):e65489. doi: 10.1371/journal.pone.0065489. Print 2013. Erratum in: PLoS One. 2013;8(12). doi:10.1371/annotation/90879c69-ebc5-40b2-9926-4a00e4f9e055. Barbone, Dario [added]; Mutti, Luciano [added].


Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression.

Barbone D, Cheung P, Battula S, Busacca S, Gray SG, Longley DB, Bueno R, Sugarbaker DJ, Fennell DA, Broaddus VC.

PLoS One. 2012;7(12):e52753. doi: 10.1371/journal.pone.0052753. Epub 2012 Dec 26.


Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent.

Hurwitz JL, Stasik I, Kerr EM, Holohan C, Redmond KM, McLaughlin KM, Busacca S, Barbone D, Broaddus VC, Gray SG, O'Byrne KJ, Johnston PG, Fennell DA, Longley DB.

Eur J Cancer. 2012 May;48(7):1096-107. doi: 10.1016/j.ejca.2011.11.009. Epub 2011 Dec 10.


Rapid generation of in vitro multicellular spheroids for the study of monoclonal antibody therapy.

Phung YT, Barbone D, Broaddus VC, Ho M.

J Cancer. 2011;2:507-14. Epub 2011 Oct 13.


The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance.

Barbone D, Ryan JA, Kolhatkar N, Chacko AD, Jablons DM, Sugarbaker DJ, Bueno R, Letai AG, Coussens LM, Fennell DA, Broaddus VC.

Cell Death Dis. 2011 Jun 23;2:e174. doi: 10.1038/cddis.2011.58.


Taurolidine and oxidative stress: a rationale for local treatment of mesothelioma.

Aceto N, Bertino P, Barbone D, Tassi G, Manzo L, Porta C, Mutti L, Gaudino G.

Eur Respir J. 2009 Dec;34(6):1399-407. doi: 10.1183/09031936.00102308. Epub 2009 May 21.


Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma.

Bidlingmaier S, He J, Wang Y, An F, Feng J, Barbone D, Gao D, Franc B, Broaddus VC, Liu B.

Cancer Res. 2009 Feb 15;69(4):1570-7. doi: 10.1158/0008-5472.CAN-08-1363. Epub 2009 Feb 3.


Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids.

Yang TM, Barbone D, Fennell DA, Broaddus VC.

Am J Respir Cell Mol Biol. 2009 Jul;41(1):14-23. doi: 10.1165/rcmb.2008-0320OC. Epub 2008 Dec 18.


mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids.

Wilson SM, Barbone D, Yang TM, Jablons DM, Bueno R, Sugarbaker DJ, Nishimura SL, Gordon GJ, Broaddus VC.

Am J Respir Cell Mol Biol. 2008 Nov;39(5):576-83. doi: 10.1165/rcmb.2007-0460OC. Epub 2008 May 29.


Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids.

Barbone D, Yang TM, Morgan JR, Gaudino G, Broaddus VC.

J Biol Chem. 2008 May 9;283(19):13021-30. doi: 10.1074/jbc.M709698200. Epub 2008 Mar 13.


Malignant mesothelioma cells are rapidly sensitized to TRAIL-induced apoptosis by low-dose anisomycin via Bim.

Abayasiriwardana KS, Barbone D, Kim KU, Vivo C, Lee KK, Dansen TB, Hunt AE, Evan GI, Broaddus VC.

Mol Cancer Ther. 2007 Oct;6(10):2766-76.


Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.

Sartore-Bianchi A, Gasparri F, Galvani A, Nici L, Darnowski JW, Barbone D, Fennell DA, Gaudino G, Porta C, Mutti L.

Clin Cancer Res. 2007 Oct 1;13(19):5942-51. Erratum in: Clin Cancer Res. 2007 Nov 1;13(21):6543.


Erionite and asbestos differently cause transformation of human mesothelial cells.

Bertino P, Marconi A, Palumbo L, Bruni BM, Barbone D, Germano S, Dogan AU, Tassi GF, Porta C, Mutti L, Gaudino G.

Int J Cancer. 2007 Jul 1;121(1):12-20.


Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed.

Bertino P, Porta C, Barbone D, Germano S, Busacca S, Pinato S, Tassi G, Favoni R, Gaudino G, Mutti L.

Thorax. 2007 Aug;62(8):690-5. Epub 2007 Feb 20.


SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure.

Cacciotti P, Barbone D, Porta C, Altomare DA, Testa JR, Mutti L, Gaudino G.

Cancer Res. 2005 Jun 15;65(12):5256-62.

Supplemental Content

Loading ...
Support Center